Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial

  • Aaron R. Hansen
  • , Stephan Probst
  • , Jean Mathieu Beauregard
  • , Benjamin L. Viglianti
  • , Jeff M. Michalski
  • , Scott T. Tagawa
  • , Oliver Sartor
  • , Ronald F. Tutrone
  • , Orhan K. Oz
  • , Kevin D. Courtney
  • , Ebrahim S. Delpassand
  • , Luke T. Nordquist
  • , Medhat M. Osman
  • , Kim N. Chi
  • , Richard Sparks
  • , Noble George
  • , Sara M. Hawley
  • , Wenting Wu
  • , Jessica D. Jensen
  • , Neil E. Fleshner

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Fingerprint

Dive into the research topics of 'Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science